3/

Notice of Allowability	Application No.	Applicant(s)
	10/621,505	YOSHIHARA ET AL.
	Examiner	Art Unit
	Thoi V. Duong	2871
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed March 09, 2007.		
2.  The allowed claim(s) is/are <u>1-7,14,15 and 17</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
·		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) None	5. Notice of Informal F	Patent Application
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	' '
Information Disclosure Statements (PTO/SB/08),     Paper No./Mail Date	Paper No./Mail Da 7.	te ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's Statements. ☐ Other	ent of Reasons for Allowance

Application/Control Number: 10/621,505

Art Unit: 2871

## **DETAILED ACTION**

1. This office action is in response to the Amendment filed March 09, 2007.

Accordingly, claims 1 and 14 were amended, and claims 8-13 and 16 were cancelled. Currently, claims 1-7, 14, 15 and 17 are pending in this application.

## Allowable Subject Matter

2. Claims 1-7, 14, 15 and 17 are allowed.

The following is an examiner's statement of reasons for allowance: none of the prior art of record fairly suggests or shows all of the limitations as claimed. Specifically,

Re claims 1 and 14, none of the prior art of record discloses, in combination with other limitations as claimed, a liquid crystal display device as well as a manufacturing method of the same comprising a temperature range of either one of a cholesteric phase and a chiral nematic phase of a phase sequence of said liquid crystal, the phase sequence being either one of an isotropic phase - cholesteric phase - chiral smectic C phase and an isotropic phase -chiral nematic phase - chiral smectic C phase from a higher-temperature side, has a temperature width of not less than 3°C.

The most relevant reference, US 5,746,939 to Taniguchi et al. (Taniguchi), fails to disclose or suggest the claimed invention. Taniguchi prefers a liquid crystal material having a sufficiently broad temperature range of 5°C or more for cholesteric phase (Ch phase); however, this particular temperature range is applicable to the phase sequence  $150 \rightarrow Ch \rightarrow SmA \rightarrow SmC^*$  (col. 3, lines 1-10 and 43-48; and col. 7, claims 6 and 7). Taniguchi is silent about the temperature range of the cholesteric phase in the phase sequence  $150 \rightarrow Ch \rightarrow SmC^*$ .

Art Unit: 2871

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thoi V. Duong whose telephone number is (571) 272-2292. The examiner can normally be reached on Monday-Friday from 8:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Nelms, can be reached at (571) 272-1787.

Tharmsmy

Thoi V. Duong

05/08/2007